Draft vaping regulations: Four Years Later, It's Time to Finalize a Federal Ban on Flavoured Vapes Français
, June 19, 2025 /CNW/ - After four years of government inaction, antitobacco groups are calling on the new federal government to accelerate the approval of public health measures to protect children from nicotine addiction.
On June 19, 2021, Health Canada released draft regulations that would have stopped tobacco and nicotine companies from adding flavourings and sweeteners to vaping liquids. At the time, Health Canada said the regulation would help address the "rapid increase in youth vaping in Canada" and acknowledged that "desirable flavours [are] believed to have contributed to the rise in youth vaping."
Yet despite repeated promises by the Trudeau government that this important protective measure would be finalized " soon," tobacco companies have continued to receive permission to use flavours that lure young people into nicotine use, a practice they maintain to this day.
"Banning nicotine flavourings in vaping products sold on the open market is a fundamental and necessary measure to protect young people from becoming addicted to tobacco industry products," explained Flory Doucas, Co-Director of the Quebec Coalition of Tobacco Control.
"Without these controls, companies will continue to exploit the curiosity and taste preferences of youth, drawing them into drug use that poses significant risks to their developing brains and overall health. Flavourings also make the products more fun and seemingly more innocuous to use, which diminishes young people's understanding of the inherent product risks."
Despite support for a flavour ban from major health agencies, provincial and territorial governments, as well as repeated calls for such a ban by provincial and federal medical officers of health, including Dr. Theresa Tam from the federal government's own Public Health Agency, these regulations have been repeatedly postponed following meetings with tobacco and nicotine companies.
"Bowing to industry pressure has already harmed hundreds of thousands of Canadian children and will continue to do so until these products are taken off the market," said Cynthia Callard, Executive Director of Physicians for a Smoke-Free Canada.
Health Canada's most recent Canadian Student Alcohol and Drug Survey estimated that 27% of Grade 12 students were vaping, half of whom do so every day. "This year's high school graduates were in middle school when these regulations were first proposed. Endless dithering by the federal government has needlessly allowed an entire new school cohort to be victimized by nicotine marketing," added Ms. Callard.
Using data from this government survey, Physicians for a Smoke-Free Canada has added a counter to its Blog to display the estimated number of high school students who have started vaping since the Honourable Marjorie Michel became Health minister on May 13, 2025.
Les Hagen, Executive Director of Action on Smoking & Health challenged government inaction: "How many more teenagers need to become addicted to nicotine before the federal government decides to finally step in? Can the Health Minister please inform Canadians of the threshold number of addicted youth required to justify federal restrictions on flavoured vaping products? Will the minister follow the advice of her Chief Medical Health Officer, and the medical officer in every province and territory?"
"Measures to prevent addiction and disease among children contribute to a strong Canadian economy and serve a nation-wide purpose" added Cynthia Callard."We urge Minister Michel to forward the finalized regulation to cabinet for approval without further delay."
SOURCE Quebec Coalition for Tobacco Control
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Global News
4 hours ago
- Global News
Unexpected financial costs plague expectant Winnipeg couple
Expecting the birth of a first child is an exciting time for any parents-to-be, but for one Winnipeg couple, what should be a joyous occasion is turning into a bureaucratic headache. Andrew and Nikka Worth are expecting a baby at the end of June, but due to what they say is an overly complicated process related to Nikka's legal status in Canada, they're looking at massive costs associated with her pregnancy, some of which they've already begun paying out of pocket. The couple, who met at a local church, was married last September, and Nikka — originally from the Philippines — is waiting to receive her permanent resident status. Andrew said the process seemed fairly straightforward, until the pregnancy came into play. 'We'd already submitted the documentation with the federal government to get Nikka her PR,' he told Global Winnipeg. 'After that, we found out we were pregnant, so I began the process of trying to get her covered (under) my health card. Looking at the website, it looked like it shouldn't be a problem.' Story continues below advertisement Unfortunately, it turned out to be more complicated than the couple thought. Nikka's legal status in Manitoba is as a visitor record holder, and Andrew said he was surprised to learn that the only way someone with that status can get health coverage is if their spouse is a temporary resident with a work permit. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Andrew, a Canadian citizen, didn't meet that criteria. 'We got a letter in the mail saying that the request had been rejected,' he said. 'We reached out to our MLA, and at the same time, the families minister of Manitoba, the health minister of Manitoba, (premier) Wab Kinew. 'After all that kind of petered out and basically we were told to wait for the PR, we thought maybe we could go through the appeal board and maybe the ombudsman.' That process, he said, led to a lot of contradictory and confusing information, and ultimately another dismissal of their request. While they await approval of Nikka's permanent residency, their baby is still on its way, which means regular doctors' appointments and more — all of which they've had to pay for directly. 'We've actually been paying out of pocket for all of my doctors' appointments, even the ultrasounds… everything that is required — even the lab tests, blood work, and all of that,' Nikka said. Story continues below advertisement 'We've paid $5,000 already out of pocket, and that doesn't include the hospital bills yet, because they haven't delivered the baby, and also the doctor's fee.' Those costs, she said, could come to $6,000 per day, depending on the type of delivery and whether there are any additional complications. If for any reason Nikka has to stay in the ICU because of complications, that would add an additional $16,000 to the hospital bill. Because the child will immediately be a Canadian citizen once he or she is born, Andrew said some of the rules don't make a lot of sense. 'To me, it's strange that they would have the stipulation that any child born on Canadian soil is a Canadian citizen… but for billing purposes, they are not. 'It just seems like a weird kind of misstep or interpretation.'


Globe and Mail
5 hours ago
- Globe and Mail
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
Abbott Laboratories ABT recently received Health Canada approval for the i-STAT TBI test cartridge for use with whole blood. It is designed to help clinicians assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. The latest approval expands the company's TBI test offerings, which include the i-STAT TBI Plasma test, and the ARCHITECT and Alinity i lab test (serum and plasma). ABT Stock's Likely Trend Following the News Following the announcement, Abbott's shares edged down 1.2%, finishing at $134.01 on Monday. On a positive note, Abbott's accelerated investments in the R&D pipeline are yielding positive results. Hence, we expect the market sentiment toward ABT stock to turn positive surrounding the latest approval. Abbott holds a market capitalization of $230.37 billion. The company's earnings yield of 3.9% surpasses the industry's 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters. About Abbott's i-STAT TBI Test Cartridge Usage For decades, standard TBI assessment has remained the same, with doctors leveraging tools, such as the Canadian CT Head Rule, which uses the Glasgow Coma Scale to detect brain tissue damage or lesions. However, the whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older with suspected mild traumatic brain injury (mTBI), commonly known as a concussion. The blood test provides objective information and helps remove the ambiguity of a standard concussion assessment. The i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury. The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), which are released into the blood stream during a significant brain injury. Testing for these two biomarkers following an injury can provide essential and objective information about a patient's condition and help healthcare providers choose an appropriate treatment plan. Industry Prospect Favors ABT Per a report by Brain Injury Canada, an estimated 165 million Canadians will experience a TBI in 2025. Likewise, the Government of Canada released a report stating that each year more than 20 million people are hospitalized for TBI in the country, and the injury can range from mild to severe and include concussions. Even a mild form of TBI can have long-term consequences. Among all types of TBIs, concussions are the most common, accounting for approximately 80-95% of such injuries. Another Development by Abbott Last month, Abbott received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). ABT Stock Price Performance Over the past year, Abbott's shares have risen 27.3%, surpassing the industry 's 8.4% growth. ABT's Zacks Rank and Key Picks Abbott currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Align Technology ALGN, Hims & Hers Health HIMS and Cencora COR. Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry's 9.9%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry's 3.3% decline in the past year. ALGN sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry's -10.1%. Shares of the company have surged 129.7% compared with the industry's 35.9% gain. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.8%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 25.9% against the industry's 14.4% decline. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report This article originally published on Zacks Investment Research (


Cision Canada
5 hours ago
- Cision Canada
Approved by Health Canada - Zilia Ocular: A World First Set to Revolutionize Eye Care
QUEBEC CITY, June 19, 2025 /CNW/ - Zilia, a Canadian health technology company, is proud to announce that its flagship product, the Zilia Ocular™, has received approval from Health Canada. It is the first device in the world authorized to measure oxygen saturation in the eye—a breakthrough that has the potential to redefine eye care. Developed in Quebec City, the Zilia Ocular is a revolutionary retinal camera equipped with a patented optical technology that enables the non-invasive measurement of oxygenation in the eye. This metabolic biomarker gives eye care professionals an entirely new window into the physiological state of the eye, with the goal of detecting issues well before structural damage occurs. "This represents a true paradigm shift," said Dr. Patrick Sauvageau, optometrist, CEO and co-founder of Zilia. "By measuring retinal oxygenation in real time, we aim to help clinicians detect and manage eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration more effectively." A Breakthrough at the Heart of Oculomics As oculomics—an emerging field that uses the eye as a gateway to assess overall health—gains traction globally, biomarkers like oxygen saturation are paving the way for a more preventive, personalized, and data-driven approach to medicine. The Zilia Ocular is at the forefront of this movement, introducing a layer of analysis that was previously inaccessible in clinical settings. Zilia plans to launch its device in Canada in the coming months, followed by expansion into the United States and Europe. About Zilia Zilia is a health technology company developing a groundbreaking platform to non-invasively measure biomarkers in the eye, with an initial focus on ocular oximetry. By integrating advanced photonics and artificial intelligence, Zilia's first-of-kind technology is intended to leverage the eye's optical properties and direct connections to the vascular system and the brain to capture critical information on ocular and overall health.